Xbrane Biopharma AB (publ) (STO:XBRANE)
Sweden
· Delayed Price · Currency is SEK 0.2085
-0.0050 (-2.34%)
Mar 31, 2025, 3:00 PM CET
Xbrane Biopharma AB Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Cash & Equivalents | 124.33 | 65.4 | 193.99 | 295.18 | 243.14 | Upgrade
|
| Cash & Short-Term Investments | 124.33 | 65.4 | 193.99 | 295.18 | 243.14 | Upgrade
|
| Cash Growth | 90.10% | -66.29% | -34.28% | 21.40% | 48.08% | Upgrade
|
| Accounts Receivable | 16.85 | - | 1.34 | - | 51.38 | Upgrade
|
| Other Receivables | 16.97 | 71.18 | 46.12 | 108.3 | 23.79 | Upgrade
|
| Receivables | 33.83 | 71.18 | 47.46 | 108.3 | 75.17 | Upgrade
|
| Inventory | 246.9 | 106.86 | 50.26 | - | - | Upgrade
|
| Prepaid Expenses | 67.05 | 16.89 | 13 | 2.31 | 1.21 | Upgrade
|
| Other Current Assets | 133.79 | 201.37 | 208.81 | 155.21 | 54.96 | Upgrade
|
| Total Current Assets | 605.9 | 461.69 | 513.52 | 561.01 | 374.48 | Upgrade
|
| Property, Plant & Equipment | 64.9 | 88.2 | 71.05 | 73.8 | 14.14 | Upgrade
|
| Goodwill | - | - | - | - | 58.45 | Upgrade
|
| Long-Term Deferred Charges | 167.69 | 99.67 | 102 | 49.67 | 4.08 | Upgrade
|
| Other Long-Term Assets | 3.95 | 3.95 | 3.95 | 3.95 | 12.61 | Upgrade
|
| Total Assets | 842.43 | 653.51 | 690.52 | 688.43 | 463.76 | Upgrade
|
| Accounts Payable | 242.57 | 30.97 | 23.3 | 41.39 | 29.55 | Upgrade
|
| Accrued Expenses | 41.15 | 59.23 | 66.48 | 65.76 | 41.22 | Upgrade
|
| Current Portion of Long-Term Debt | 82.5 | 62.5 | - | - | - | Upgrade
|
| Current Portion of Leases | 13.27 | 13.37 | 9.16 | 7.91 | 2.27 | Upgrade
|
| Current Unearned Revenue | 62.3 | 159.6 | 136.06 | 95.39 | 115.96 | Upgrade
|
| Other Current Liabilities | 96.15 | 0.88 | 1.56 | 9.22 | 0 | Upgrade
|
| Total Current Liabilities | 537.94 | 326.56 | 236.57 | 219.67 | 188.99 | Upgrade
|
| Long-Term Debt | 66.37 | 112.9 | - | - | - | Upgrade
|
| Long-Term Leases | 29.58 | 42.71 | 29.06 | 36.48 | 4 | Upgrade
|
| Long-Term Unearned Revenue | - | - | - | 0.54 | 8.26 | Upgrade
|
| Other Long-Term Liabilities | -0 | 0.01 | - | - | 4.81 | Upgrade
|
| Total Liabilities | 633.89 | 482.17 | 265.63 | 256.69 | 206.06 | Upgrade
|
| Common Stock | 343.5 | 6.68 | 6.17 | 5.61 | 4.98 | Upgrade
|
| Additional Paid-In Capital | 1,395 | 1,429 | 1,294 | 1,134 | 773.72 | Upgrade
|
| Retained Earnings | -1,540 | -1,274 | -885.83 | -713.31 | -524.94 | Upgrade
|
| Comprehensive Income & Other | 10.23 | 10.12 | 10.32 | 5.16 | 3.95 | Upgrade
|
| Shareholders' Equity | 208.54 | 171.34 | 424.89 | 431.74 | 257.71 | Upgrade
|
| Total Liabilities & Equity | 842.43 | 653.51 | 690.52 | 688.43 | 463.76 | Upgrade
|
| Total Debt | 191.72 | 231.48 | 38.22 | 44.38 | 6.26 | Upgrade
|
| Net Cash (Debt) | -67.39 | -166.08 | 155.77 | 250.8 | 236.88 | Upgrade
|
| Net Cash Growth | - | - | -37.89% | 5.88% | 53.06% | Upgrade
|
| Net Cash Per Share | -0.05 | -5.79 | 6.09 | 10.63 | 13.08 | Upgrade
|
| Filing Date Shares Outstanding | 1,529 | 29.81 | 27.51 | 25.04 | 22.2 | Upgrade
|
| Total Common Shares Outstanding | 1,529 | 29.81 | 27.51 | 25.04 | 22.2 | Upgrade
|
| Working Capital | 67.96 | 135.14 | 276.96 | 341.34 | 185.49 | Upgrade
|
| Book Value Per Share | 0.14 | 5.75 | 15.45 | 17.24 | 11.61 | Upgrade
|
| Tangible Book Value | 208.54 | 171.34 | 424.89 | 431.74 | 199.26 | Upgrade
|
| Tangible Book Value Per Share | 0.14 | 5.75 | 15.45 | 17.24 | 8.98 | Upgrade
|
| Machinery | - | 61.93 | - | 43.49 | 28.4 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.